NASDAQ:NXL Nexalin Technology 11/8/2024 Earnings Report $1.82 0.00 (0.00%) As of 04:00 PM Eastern Earnings HistoryForecast Nexalin Technology EPS ResultsActual EPS-$0.23Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANexalin Technology Revenue ResultsActual Revenue$0.04 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANexalin Technology Announcement DetailsQuarterDate11/8/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsNexalin Technology's next earnings date is estimated for Friday, May 9, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Nexalin Technology Earnings HeadlinesNexalin Technology receives IRB approval in Brazil, begins trialApril 24, 2025 | markets.businessinsider.comNexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and InsomniaApril 24, 2025 | globenewswire.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 30, 2025 | Paradigm Press (Ad)Nexalin completes five phases of virtual clinic, digital research systemApril 24, 2025 | markets.businessinsider.comNexalin Technology files $50M common stock offeringApril 23, 2025 | msn.comNexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient ManagementApril 23, 2025 | globenewswire.comSee More Nexalin Technology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email. Email Address About Nexalin TechnologyNexalin Technology (NASDAQ:NXL), a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.View Nexalin Technology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings Will Make or Break the Stock's Comeback CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of Earnings Upcoming Earnings Airbnb (5/1/2025)Apple (5/1/2025)Amazon.com (5/1/2025)Amgen (5/1/2025)Linde (5/1/2025)MercadoLibre (5/1/2025)Monster Beverage (5/1/2025)Strategy (5/1/2025)Atlassian (5/1/2025)Arthur J. Gallagher & Co. (5/1/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
